AbCellera Biologics Inc. (ABCL) Social Stream



AbCellera Biologics Inc. (ABCL): $10.65

0.54 (+5.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABCL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

AbCellera Biologics Inc (ABCL) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering AbCellera Biologics Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 4 $55 $25 $45.25 $9.54 374.32%
2021-12-05 5 $53 $25 $40.8 $9.54 327.67%
2021-12-19 7 $53 $25 $39.833 $9.54 317.54%
2021-12-21 7 $53 $25 $38 $9.54 298.32%
2022-02-11 5 $45 $25 $33 $9.54 245.91%
2022-02-25 5 $40 $20 $30 $9.54 214.47%
2022-02-28 5 $40 $20 $29.6 $9.54 210.27%

The Trend in the Analyst Price Target


Over the past 46 weeks, ABCL's average price target has gone down $22.8.

ABCL reports an average of 155.36% for its upside potential over the past 47 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-08 2 55 45 51.6 29.09 77.38%
2021-08-01 2 55 25 47.2 15.17 211.14%
2021-08-28 2 55 25 45.4 17.58 158.25%
2021-11-19 5 53 25 40.8 15.80 158.23%
2021-12-05 5 53 25 40.8 14.02 191.01%

ABCL Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 5 0 0 0 0 5

The Trend in the Broker Recommendations


Over the past 92 days, ABCL's average broker recommendation rating improved by 0.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how AbCellera Biologics Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1010.82% of that group.
  • In the context of stocks in the large market cap category, AbCellera Biologics Inc's number of analysts covering the stock is greater than 106.5% of them.
  • To contextualize these metrics, consider that out of stocks in the large market cap category, AbCellera Biologics Inc's variance in analysts' estimates is lower than -792.68% of them.
  • AbCellera Biologics Inc's average analyst price target is greater than 213.29% of stocks in the large market cap category.

Stocks similar to AbCellera Biologics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are VIR, VCEL, and TIL.

Is ABCL a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4118 seconds.